Natixis Advisors
TXMD icon

Natixis Advisors’s TherapeuticsMD TXMD Stock Holding History

Natixis Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,559
Closed -$677K – 1095
2018
Q4 		$677K Sell
3,559
-826
-19% -$201K 0.01% 982
2018
Q3 		$1.44M Buy
+4,385
New +$1.34M 0.01% 864

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Natixis Advisors's TXMD Position: Q1 2019 in Review

Natixis Advisors sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 3,559 shares — an estimated $677K sold.

Natixis Advisors first reported a position in TXMD in Q3 2018 and held it in 2 quarters. The position peaked at $1.44M in Q3 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

  • Natixis Advisors reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
  • Natixis Advisors sold 3,559 TherapeuticsMD shares in Q1 2019, an estimated $677K.
  • Natixis Advisors first reported a position in TherapeuticsMD in Q3 2018 and held it in 2 quarters.
  • Natixis Advisors's TherapeuticsMD position peaked at $1.44M in Q3 2018.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on Natixis Advisors's 13F filing for Q1 2019, filed 15 May 2019.